» Articles » PMID: 11960372

Constitutive Stat3 Activity Up-regulates VEGF Expression and Tumor Angiogenesis

Abstract

Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis. While tyrosine kinases signal through multiple pathways, signal transducer and activation of transcription 3 (Stat3) is a point of convergence for many of these and is constitutively activated with high frequency in a wide range of cancer cells. Here, we show that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines. An activated Stat3 mutant (Stat3C) up-regulates VEGF expression and stimulates tumor angiogenesis. Stat3C-induced VEGF up-regulation is abrogated when a Stat3-binding site in the VEGF promoter is mutated. Furthermore, interrupting Stat3 signaling with dominant-negative Stat3 protein or Stat3 antisense oligonucleotide in tumor cells down-regulates VEGF expression. Consistent with an important role of Stat3 in VEGF up-regulation induced by various oncogenic tyrosine kinases, v-Src-mediated VEGF expression is inhibited when Stat3 signaling is blocked. Moreover, chromatin immunoprecipitation assays indicate that Stat3 protein binds to the VEGF promoter in vivo and mutation of a Stat3-binding site in the VEGF promoter abrogates v-Src-induced VEGF promoter activity. These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.

Citing Articles

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers.

Manore S, Zhuang C, Najjar M, Wong G, Bindal S, Watabe K Cells. 2025; 13(24).

PMID: 39768178 PMC: 11674475. DOI: 10.3390/cells13242087.


Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.

Zhu Q, Zhang K, Cao Y, Hu Y Cancer Cell Int. 2024; 24(1):385.

PMID: 39568023 PMC: 11577656. DOI: 10.1186/s12935-024-03557-1.


Non-metabolic enzyme function of pyruvate kinase M2 in breast cancer.

Jemal M, Getinet M, Amare G, Tegegne B, Baylie T, Mengistu E Front Oncol. 2024; 14:1450325.

PMID: 39411137 PMC: 11473492. DOI: 10.3389/fonc.2024.1450325.


Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems-An Integrated Approach towards Anticancer Synergism and Targeted Delivery.

Corte-Real M, Veiga F, Paiva-Santos A, Pires P Pharmaceutics. 2024; 16(9).

PMID: 39339235 PMC: 11434718. DOI: 10.3390/pharmaceutics16091200.


Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis.

Engin A Adv Exp Med Biol. 2024; 1460:329-356.

PMID: 39287857 DOI: 10.1007/978-3-031-63657-8_11.